R D Christensen1, D K Lambert1, D S Richards2. 1. Department of Women and Newborns, Intermountain Healthcare, Salt Lake City, UT, USA. 2. 1] Department of Women and Newborns, Intermountain Healthcare, Salt Lake City, UT, USA [2] Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Abstract
OBJECTIVE: The time between onset of fetal hypoxia and first appearance of nucleated red blood cells (NRBCs) in the blood can conceptually be divided into two periods; (1) the 'erythropoietin (EPO) generation time', which previous fetal studies suggest is 4 to 5 h, and (2) the 'NRBC emergence time'. In this study, we estimated the latter as the time required for NRBC to appear in the blood after administering a dose of recombinant EPO. STUDY DESIGN: This was a retrospective analysis of data from a multihospital healthcare system (Intermountain Healthcare). Data were included only for neonates born ≥34 weeks gestation between the dates 1 January 2005 and 31 October 2012 and only if they received a dose of darbepoetin during their neonatal intensive care unit stay and had one or more complete blood cell counts (CBCs) obtained during the 3-day period before the dose was given and one or more CBCs in the 7-day period after the dose. RESULT: The study involved 31 neonates who received 34 doses of darbepoetin. Seven doses were 4 μg kg(-1) and twenty-seven doses were 10 μg kg(-1). Twenty-six CBCs were obtained during the 24-h period following the darbepoetin dose and none had NRBC identified. NRBC first appeared in the blood between 24 and 36 h after the dose. Recipients of the higher dose generally had a higher peak NRBC count but the NRBC 'emergence time' did not appear to depend on dose. CONCLUSION: Following fetal hypoxia, transcription and translation of the EPO gene result in an elevation in plasma EPO concentration. Previous fetal studies suggest this process requires 4 to 5 h. The present studies suggest that, following the increase in plasma EPO, NRBC emerge into the circulation in ≥24 h. If this model serves as a reasonable estimate, it suggests that neonates with an elevated NRBC count at birth had the onset of hypoxia at least 28 to 29 h before birth.
OBJECTIVE: The time between onset of fetal hypoxia and first appearance of nucleated red blood cells (NRBCs) in the blood can conceptually be divided into two periods; (1) the 'erythropoietin (EPO) generation time', which previous fetal studies suggest is 4 to 5 h, and (2) the 'NRBC emergence time'. In this study, we estimated the latter as the time required for NRBC to appear in the blood after administering a dose of recombinant EPO. STUDY DESIGN: This was a retrospective analysis of data from a multihospital healthcare system (Intermountain Healthcare). Data were included only for neonates born ≥34 weeks gestation between the dates 1 January 2005 and 31 October 2012 and only if they received a dose of darbepoetin during their neonatal intensive care unit stay and had one or more complete blood cell counts (CBCs) obtained during the 3-day period before the dose was given and one or more CBCs in the 7-day period after the dose. RESULT: The study involved 31 neonates who received 34 doses of darbepoetin. Seven doses were 4 μg kg(-1) and twenty-seven doses were 10 μg kg(-1). Twenty-six CBCs were obtained during the 24-h period following the darbepoetin dose and none had NRBC identified. NRBC first appeared in the blood between 24 and 36 h after the dose. Recipients of the higher dose generally had a higher peak NRBC count but the NRBC 'emergence time' did not appear to depend on dose. CONCLUSION: Following fetal hypoxia, transcription and translation of the EPO gene result in an elevation in plasma EPO concentration. Previous fetal studies suggest this process requires 4 to 5 h. The present studies suggest that, following the increase in plasma EPO, NRBC emerge into the circulation in ≥24 h. If this model serves as a reasonable estimate, it suggests that neonates with an elevated NRBC count at birth had the onset of hypoxia at least 28 to 29 h before birth.
Authors: Robert D Christensen; Vickie L Baer; Philip V Gordon; Erick Henry; Cody Whitaker; Robert L Andres; Sterling T Bennett Journal: Pediatrics Date: 2012-04-16 Impact factor: 7.124
Authors: Teresa L Warwood; Robin K Ohls; Susan E Wiedmeier; Diane K Lambert; Cory Jones; Scott H Scoffield; Gupta Neeraj; Peter Veng-Pedersen; Robert D Christensen Journal: J Perinatol Date: 2005-11 Impact factor: 2.521
Authors: S Perrone; P Vezzosi; M Longini; B Marzocchi; D Tanganelli; M Testa; T Santilli; G Buonocore Journal: Arch Dis Child Fetal Neonatal Ed Date: 2005-03 Impact factor: 5.747
Authors: Antonette T Dulay; Irina A Buhimschi; Guomao Zhao; Guoyang Luo; Sonya Abdel-Razeq; Michael Cackovic; Victor A Rosenberg; Christian M Pettker; Stephen F Thung; Mert O Bahtiyar; Vineet Bhandari; Catalin S Buhimschi Journal: Am J Obstet Gynecol Date: 2008-04 Impact factor: 8.661
Authors: Sean C Blackwell; Mordechai Hallak; John W Hotra; Jerrie Refuerzo; Sonia S Hassan; Robert J Sokol; Yoram Sorokin Journal: Biol Neonate Date: 2003-12-23
Authors: James L Wynn; Philip O Scumpia; Blair T Stocks; Joann Romano-Keeler; Mhd Wael Alrifai; Jin-Hua Liu; Annette S Kim; Catherine E Alford; Pranathi Matta; Jörn-Hendrik Weitkamp; Daniel J Moore Journal: J Immunol Date: 2015-06-22 Impact factor: 5.422